# SCYX catalysts: SCYNEXIS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/scyx/catalysts

> SCYNEXIS INC (SCYX) has 2 upcoming catalysts. The next is the SCY-770 interim data readout, 2H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for SCYX?

SCYNEXIS INC (SCYX) has 2 upcoming catalysts. The next is the SCY-770 interim data readout, 2H 2027. Press release filed with the SEC (EX-99): "Early efficacy readout GSK-BREXAFEMME partnership expected in 2H 2027 with has potential to deliver up to $146M study completion in 2H in sales milestones + royalties 2028 Experienced Leadership with Proven" [Calendar and source filings](https://sec-api.dev/companies/scyx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-134476, https://www.sec.gov/Archives/edgar/data/1178253/000119312526134476/d114312dex991.htm (retrieved 2026-11-12). Last confirmed 2026-05-11. Cite: https://sec-api.dev/companies/scyx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | SCYNEXIS INC |
| Ticker | SCYX (Nasdaq) |
| SEC CIK | 1178253 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/scyx |

## Cash runway

Cash $47.2M as of 2026-09-30; quarterly burn $7.5M; about 19.0 months of runway at that rate (XBRL company facts, accession 0001193125-26-448644).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2022 | [Brexafemme (ibrexafungerp) FDA approval](https://sec-api.dev/pdufa/ibrexafungerp) | SCYX |  | completed, approved | "In June 2021 and December 2022, we announced that the United States (U.S.) Food and Drug Administration (FDA) approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178253/000095017025038044/scyx-20241231.htm)) |
| November 7, 2025 | [Brexafemme (ibrexafungerp) primary completion](https://sec-api.dev/pdufa/ibrexafungerp) | SCYX | Candidiasis, Invasive; Candidemia | withdrawn | "NCT05178862 (A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-07 (ACTUAL); Lead Sponsor Scynexis, Inc.; Results First Posted 2026-08-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05178862)) |
| Q4 2026 | [SCY-770 trial start](https://sec-api.dev/pdufa/scy-770) | SCYX |  | scheduled | "SCYNEXIS is expected to begin a Phase 2 proof-of-concept study in ADPKD patients in Q4 2026, with an anticipated early efficacy readout in second half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178253/000119312526133250/d118823dex991.htm)) |
| 2H 2027 | [SCY-770 interim data readout](https://sec-api.dev/pdufa/scy-770) | SCYX |  | scheduled | "Early efficacy readout GSK-BREXAFEMME partnership expected in 2H 2027 with has potential to deliver up to $146M study completion in 2H in sales milestones + royalties 2028 Experienced Leadership with Proven" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178253/000119312526134476/d114312dex991.htm)) |
| April 1, 2031 | [SCY-770 topline data readout](https://sec-api.dev/pdufa/scy-770) | SCYX |  | scheduled | "Each Common Warrant is exercisable for one share of common stock (or Pre-Funded Warrant in lieu thereof) at an exercise price of $1.20 per share, and will be exercisable beginning on the effective date of the stockholder approval relating to the proposed increase of our authorized shares of common stock and will expire on 5:00 p.m. (New York City time) on the earlier of (i) April 1, 2031 or (ii) the 30th day after we publicly release topline data at Week 48 from our Phase 2 proof-of-concept clinical study evaluating SCY-770 in patients with ADPKD." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000011/scyx-20260331.htm)) |

## Drugs

- [SCY-770](https://sec-api.dev/pdufa/scy-770): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/scyx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SCYX catalysts: SCYNEXIS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/scyx/catalysts

```bibtex
@misc{secapidev_companies_scyx_catalysts_20261116,
  title        = {SCYX catalysts: SCYNEXIS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/scyx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_scyx_catalysts_20261116","title":"SCYX catalysts: SCYNEXIS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/scyx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
